MX2017000698A - Uso terapeutico de la proteina de union a neurotrofina p75ntr. - Google Patents

Uso terapeutico de la proteina de union a neurotrofina p75ntr.

Info

Publication number
MX2017000698A
MX2017000698A MX2017000698A MX2017000698A MX2017000698A MX 2017000698 A MX2017000698 A MX 2017000698A MX 2017000698 A MX2017000698 A MX 2017000698A MX 2017000698 A MX2017000698 A MX 2017000698A MX 2017000698 A MX2017000698 A MX 2017000698A
Authority
MX
Mexico
Prior art keywords
binding protein
therapeutic use
neurotrophin binding
p75ntr neurotrophin
p75ntr
Prior art date
Application number
MX2017000698A
Other languages
English (en)
Inventor
Simon Westbrook
Original Assignee
Levicept Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Levicept Ltd filed Critical Levicept Ltd
Publication of MX2017000698A publication Critical patent/MX2017000698A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención está relacionada a un nuevo uso terapéutico de una proteína de unión a neurotrofina p75NTR y moléculas relacionadas en el tratamiento de osteoartritis.
MX2017000698A 2014-07-17 2015-07-17 Uso terapeutico de la proteina de union a neurotrofina p75ntr. MX2017000698A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1412748.4A GB201412748D0 (en) 2014-07-17 2014-07-17 Therapeutic use of P75NTR neurotrophin binding protein
PCT/GB2015/052083 WO2016009222A1 (en) 2014-07-17 2015-07-17 Therapeutic use of p75ntr neurotrophin binding protein

Publications (1)

Publication Number Publication Date
MX2017000698A true MX2017000698A (es) 2017-04-27

Family

ID=51494769

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000698A MX2017000698A (es) 2014-07-17 2015-07-17 Uso terapeutico de la proteina de union a neurotrofina p75ntr.

Country Status (17)

Country Link
US (2) US11339202B2 (es)
EP (1) EP3169347A1 (es)
JP (2) JP2017527303A (es)
KR (2) KR20170062442A (es)
CN (1) CN108137668A (es)
AU (2) AU2015288918B2 (es)
BR (1) BR112017000833A2 (es)
CA (1) CA2953061A1 (es)
EA (1) EA201700057A1 (es)
GB (1) GB201412748D0 (es)
HK (1) HK1256712A1 (es)
IL (1) IL249535B (es)
MX (1) MX2017000698A (es)
NZ (1) NZ727446A (es)
SG (1) SG11201700056RA (es)
WO (1) WO2016009222A1 (es)
ZA (1) ZA201608675B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2825208T1 (sl) 2012-03-14 2017-10-30 Levicept Ltd. P75ntr nevrotrofin vezavni protein za terapevtsko rabo
GB201316592D0 (en) * 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
GB201504691D0 (en) 2015-03-19 2015-05-06 Levicept Ltd Fusion protein
US11608371B1 (en) 2021-10-21 2023-03-21 Petmedix Ltd Therapeutic molecules

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
US9498530B2 (en) * 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
DE602005021811D1 (de) * 2004-09-13 2010-07-22 Genzyme Corp Multimere konstrukte
CN101160322A (zh) * 2005-01-28 2008-04-09 阿波罗生命科学有限公司 分子及其嵌合分子
EP1844069A4 (en) * 2005-01-28 2009-05-20 Apollo Life Sciences Ltd MOLECULES AND CHIMESE MOLECULES THEREOF
WO2007026567A1 (ja) 2005-08-30 2007-03-08 National University Corporation Chiba University ｐ７５ＮＴＲ阻害剤を有効成分として含有する鎮痛剤
WO2007070983A1 (en) 2005-12-22 2007-06-28 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
US8309088B2 (en) * 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
US20100061981A1 (en) * 2008-08-15 2010-03-11 The Salk Institute For Biological Studies p75NTR MEDIATES EPHRIN-A REVERSE SIGNALING
EP2413962A1 (en) * 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
SG175436A1 (en) * 2009-05-04 2011-12-29 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
CN102233128B (zh) 2010-11-26 2013-04-17 王延江 一种p75NTR-ECD在防治阿尔茨海默病药物中应用
ITRM20110024A1 (it) 2011-01-24 2012-07-25 Consiglio Nazionale Ricerche Uso di antagonisti del recettore p75ntr e/o di agonisti del recettore trka per il trattamento delle malattie infiammatorie croniche.
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
CN102586313A (zh) 2012-03-05 2012-07-18 中国人民解放军第三军医大学野战外科研究所 p75NTR-ED-Fc融合蛋白的制备方法及其在损伤中枢神经再生与功能恢复中的应用
SI2825208T1 (sl) 2012-03-14 2017-10-30 Levicept Ltd. P75ntr nevrotrofin vezavni protein za terapevtsko rabo
EP2674439B1 (en) * 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
GB201316592D0 (en) 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
GB201504691D0 (en) 2015-03-19 2015-05-06 Levicept Ltd Fusion protein

Also Published As

Publication number Publication date
ZA201608675B (en) 2019-11-27
BR112017000833A2 (pt) 2020-07-07
US11339202B2 (en) 2022-05-24
AU2021201611A1 (en) 2021-04-01
JP2017527303A (ja) 2017-09-21
WO2016009222A1 (en) 2016-01-21
CN108137668A (zh) 2018-06-08
AU2015288918A1 (en) 2017-01-12
EP3169347A1 (en) 2017-05-24
GB201412748D0 (en) 2014-09-03
IL249535B (en) 2021-01-31
KR20170062442A (ko) 2017-06-07
JP7365378B2 (ja) 2023-10-19
NZ727446A (en) 2022-02-25
SG11201700056RA (en) 2017-02-27
KR20230004967A (ko) 2023-01-06
US20170204156A1 (en) 2017-07-20
CA2953061A1 (en) 2016-01-21
AU2015288918B2 (en) 2021-02-25
IL249535A0 (en) 2017-02-28
JP2021177766A (ja) 2021-11-18
EA201700057A1 (ru) 2017-06-30
US20230093211A1 (en) 2023-03-23
HK1256712A1 (zh) 2019-10-04

Similar Documents

Publication Publication Date Title
IL255780A (en) Therapeutic combinations and methods for treating neoplasia
PH12014501736B1 (en) Therapeutic use of p75ntr neurotrophin binding protein
EP3191098A4 (en) Combinations and dosing regimes to treat rb-positive tumors
HK1244681A1 (zh) 用於治療腫瘤形成的治療組合和方法
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
GEP20217317B (en) Combination therapy for the treatment of cancer
GB201500463D0 (en) Therapeutic molecules
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
SG10202111844VA (en) Cxcr4 binding molecules
HK1253092A1 (zh) 中和抗流感結合分子及其用途
GB201500461D0 (en) Therapeutic molecules
NZ727446A (en) Therapeutic use of p75ntr neurotrophin binding protein
ZA201704726B (en) Peptides and their use in the treatment of skin
IL257577A (en) New peptides and a combination of peptides and supports for use in immunotherapy in different types of cancer
GB201514021D0 (en) Novel Pyridines and their use in the treatment of cancer
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
PL3233174T3 (pl) Wewnątrzgałkowe dostarczanie bioaktywnych cząsteczek za pomocą jontoforezy
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment
EP3151821A4 (en) Marmelin analogs and methods of use in cancer treatment
EA201691335A1 (ru) Гексагидрофуропирролы в качестве ингибиторов pde1
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων
GB2535562B8 (en) Hydrogel compositions and their use in the treatment of symptoms induced by hypertrophic scars
HK1212920A1 (zh) 使用麥膠蛋白肽治療癌症的套件和方法
GB201710109D0 (en) Albumin-based therapeutic molecules
GB201710105D0 (en) Albumin-based therapeutic molecules